NCT07437963 2026-04-15
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07518654 2026-04-08
ThINKK-01
St. Justine's Hospital
Phase 1 Not yet recruiting
NCT07211737 2026-02-06
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07318831 2026-01-06
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07261241 2025-12-03
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Not yet recruiting
NCT07111117 2025-09-03
NEUROBLASTOTEP
Institut Curie
Phase 2 Not yet recruiting
NCT07090538 2025-07-29
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
Chinese PLA General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06948994 2025-04-29
A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma
Guangzhou Women and Children's Medical Center
Phase 1/2 Not yet recruiting
NCT06047535 2023-09-21
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
SciClone Pharmaceuticals
Phase 4 Not yet recruiting
NCT05303727 2022-07-01
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting